Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Augustina Isioma Ikusemoro: Kell vs RhD Sensitization – The Difference in RBC Destruction
Augustina Isioma Ikusemoro/LinkedIn
Apr 3, 2026, 17:11

Augustina Isioma Ikusemoro: Kell vs RhD Sensitization – The Difference in RBC Destruction

Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:

“Anti-D destroys red cells.
Anti-K stops them from being made.

That difference can change everything in fetal survival.

Most clinicians are trained to recognize RhD sensitization as a major cause of Hemolytic Disease of the Fetus and Newborn (HDFN).

But fewer appreciate that Kell sensitization can be equally — and sometimes more — dangerous.

Here’s why this matters 

While RhD antibodies destroy circulating fetal red blood cells, Anti-K antibodies suppress fetal red cell production at the bone marrow level.

This means:

  • RhD sensitization leads to hemolysis
  • Kell sensitization leads to erythropoiesis suppression

And clinically, that distinction is critical.

In RhD HDFN, anemia develops because red cells are destroyed in the fetal spleen.

In Kell-mediated HDFN, anemia develops because red cells are never produced in adequate numbers in the first place.

The result?

  • Earlier onset anemia
  • Lower reticulocyte counts
  • Less predictable disease progression
  • Severe fetal compromise even with low antibody titers

Unlike RhD disease — where bilirubin levels often reflect severity — Kell disease can progress silently until fetal anemia becomes critical.

This is why Anti-K detection during pregnancy must always trigger enhanced fetal surveillance.

And why transfusion services must prioritize:

  • K- antigen matching for sensitized patients
  • Prevention of alloimmunization in women of child-bearing age
  • Extended phenotype awareness beyond ABO and RhD

Because transfusion safety doesn’t stop at compatibility.
It continues with anticipation.

Blood Doki
Advancing transfusion safety through education, systems awareness, and clinical insight.”

Augustina Isioma Ikusemoro

Stay updated with Hemostasis Today.

Augustina Isioma Ikusemoro Blood bone marrow Erythropoiesis haemolysys HDFN Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today k-antigen Kell sensitization Medicine RBC RhD sensitisation Severe anemia
NewsFeed